In last trading session, Vir Biotechnology Inc (NASDAQ:VIR) saw 0.71 million shares changing hands with its beta currently measuring 1.14. Company’s recent per share price level of $9.57 trading at -$0.23 or -2.35% at ring of the bell on the day assigns it a market valuation of $1.32B. That closing price of VIR’s stock is at a discount of -50.99% from its 52-week high price of $14.45 and is indicating a premium of 31.45% from its 52-week low price of $6.56.

For Vir Biotechnology Inc (VIR), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.56. Splitting up the data highlights that, out of 10 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 3 suggested the stock as a Hold whereas 7 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.87 in the current quarter.

Vir Biotechnology Inc (NASDAQ:VIR) trade information

Upright in the red during last session for losing -2.35%, in the last five days VIR remained trading in the red while hitting it’s week-highest on Friday, 02/14/25 when the stock touched $9.57 price level, adding 4.4% to its value on the day. Vir Biotechnology Inc’s shares saw a change of 30.38% in year-to-date performance and have moved -0.10% in past 5-day. Vir Biotechnology Inc (NASDAQ:VIR) showed a performance of -9.12% in past 30-days.

Wall Street analysts have assigned a consensus price target of 20 to the stock, which implies a rise of 52.15% to its current value. Analysts have been projecting 20 as a low price target for the stock while placing it at a high target of 20. It follows that stock’s current price would drop -108.99% in reaching the projected high whereas dropping to the targeted low would mean a loss of -108.99% for stock’s current value.

Vir Biotechnology Inc (VIR) estimates and forecasts

This year revenue growth is estimated to fall -20.34% from the last financial year’s standing.

6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 8.14M for the same. And 4 analysts are in estimates of company making revenue of 13.66M in the next quarter. Company posted 16.79M and 56.38M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -34.12% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 15.42% while estimates for its earnings growth in next 5 years are of 8.69%.

Vir Biotechnology Inc (NASDAQ:VIR)’s Major holders

SB INVESTMENT ADVISERS (UK) LTD is the top institutional holder at VIR for having 16.68 million shares of worth $148.49 million. And as of 2024-06-30, it was holding 12.2466 of the company’s outstanding shares.

The second largest institutional holder is BLACKROCK INC., which was holding about 16.43 million shares on 2024-06-30. The number of shares represents firm’s hold over 12.1482 of outstanding shares, having a total worth of $146.26 million.

On the other hand, iShares Core S&P Smallcap ETF and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Nov 30, 2024 , the former fund manager was holding 5.9 shares of worth $56.46 million or 4.28% of the total outstanding shares. The later fund manager was in possession of 3.46 shares on Sep 30, 2024 , making its stake of worth around $33.12 million in the company or a holder of 2.51% of company’s stock.